Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Pyxis Oncology, Inc.NASDAQ: PYXS
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $4.38M fell 25.4% year over year, behind the -13.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 16.4% from the prior quarter. Over 3 fiscal years it compounded at -15.9% a year.
Context
- Selling, general & admin amounted to 160.2% of revenue in FY2025, up 2.7 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $27.02K (-99.9%) for the fiscal year ending Dec 2026, a slowdown from the -12.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.38M-16.4% QoQ
- Last fiscal yearDec 2025
- $22.19M-12.7% YoY
- LTMMar 2026
- $20.02M-13.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 22.19M USD
- Year-over-year change
- -12.7%
- 4-year CAGR
- +4.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.19M | -12.7% |
| FY2024 | 2024-12-31 | 25.42M | -22.0% |
| FY2023 | 2023-12-31 | 32.61M | -12.7% |
| FY2022 | 2022-12-31 | 37.35M | +100.1% |
| FY2021 | 2021-12-31 | 18.66M | — |
Selling, General & Admin vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's LTM Mar 2026 selling, general & admin of $20.02M is the lowest of the 10 companies compared; the peer median is $35.14M.
- Its year-over-year change of -13.1% is the 8th highest of 10, against a peer median of -3.6%.
- Selling, general & admin amounts to 144.4% of revenue for PYXS, versus a peer median of 211.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.7B | +29505.3% | +3.5% | — | |
| LTM Mar 2026 | $38.28M | -25.4% | -1.1% | 55.3% | |
| LTM Mar 2026 | $36.25M | -1.5% | -0.1% | 323.5% | |
| LTM Mar 2026 | $36.17M | -2.1% | +6.6% | 99.1% | |
ZURAZura Bio Limited | LTM Mar 2026 | $35.14M | +1.0% | +112.2% | — |
| LTM Mar 2026 | $30.28M | -34.0% | -12.3% | — | |
| LTM Mar 2026 | $27.31M | -10.2% | +10.9% | 1354.8% | |
| LTM Mar 2026 | $26.89M | -3.6% | -3.6% | 95.3% | |
| LTM Mar 2026 | $23.71M | -4.5% | +3.4% | 10537.3% | |
| LTM Mar 2026 | $20.02M | -13.1% | -15.9% | 144.4% | |
| Peer median (excluding PYXS) | $35.14M | -3.6% | +3.4% | 211.3% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 16.15M | 13.86M |
| Cost of Revenue | 0 | 0 | 0 | 475K | 2.39M |
| Gross Profit | 0 | 0 | 0 | 15.67M | 11.47M |
| Gross Margin | — | — | — | 97.1% | 82.8% |
| Research & Development | 51.05M | 86.13M | 49.59M | 58.75M | 73.7M |
| Selling, General & Admin | 18.66M | 37.35M | 32.61M | 25.42M | 22.19M |
| Operating Expenses | 69.72M | 123.48M | 82.2M | 105.13M | 95.89M |
| Depreciation & Amortization | 647K | 709K | 1.93M | 2.98M | 4.51M |
| EBITDA | (75.33M) | (120.01M) | (71.86M) | (65.51M) | (73.72M) |
| EBITDA Margin | — | — | — | -405.8% | -532.0% |
| Operating Income | (69.72M) | (123.48M) | (82.2M) | (89.46M) | (84.42M) |
| Operating Margin | — | — | — | -554.1% | -609.2% |
| Interest Income | 23K | 2.76M | 6.63M | 7.04M | 3.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6.26M) | 2.76M | 8.41M | 9.97M | 6.19M |
| Income Before Tax | (75.98M) | (120.72M) | (73.79M) | (79.5M) | (78.24M) |
| Pre-Tax Margin | — | — | — | -492.4% | -564.5% |
| Income Tax Expense | 0 | 0 | 0 | (2.16M) | 1.39M |
| Net Income | (75.98M) | (120.72M) | (73.79M) | (77.33M) | (79.62M) |
| Net Margin | — | — | — | -478.9% | -574.5% |
| EPS (Basic) | (2.53) | (3.57) | (1.85) | (1.32) | (1.28) |
| EPS (Diluted) | (2.53) | (3.57) | (1.85) | (1.32) | (1.28) |
| Weighted Avg Shares | 32.22M | 33.03M | 39.9M | 58.45M | 62.14M |
| Weighted Avg Shares (Diluted) | 32.22M | 33.03M | 39.9M | 58.45M | 62.14M |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.